Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS

Digestive Diseases and Sciences

Volumn 56, Issue 7, 2011, Pages 1962-1966

  Pimentel, Mark ^a   Morales, Walter ^a   Jee, Sam Ryong ^a   Low, Kimberly ^a   Hwang, Laura ^a   Pokkunuri, Venkata ^a   Mirocha, Jim ^a   Conklin, Jeffrey ^a   Chang, Christopher ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Post infectious irritable bowel syndrome; Rat model; Rifaximin

Indexed keywords

RIFAXIMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; FECES ANALYSIS; INTESTINE FUNCTION; INTESTINE INFECTION; IRRITABLE COLON; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTIC PROPHYLAXIS; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; DISEASE MODELS, ANIMAL; FECES; INFLAMMATORY BOWEL DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RIFAMYCINS;

EID: 79959753098     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1548-z     Document Type: Article

References (16)

1. McKendrick MW, Read NW. Irritable bowel syndrome - post salmonella infection. J Infect. 1994;29:1-3. (Pubitemid 24243103)
2. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients. BMJ. 1997;314:779-782. (Pubitemid 27117047)
3. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400-406. (Pubitemid 29119338)
4. Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol. 2003;98:327-331. (Pubitemid 36232381)
5. Barber R, Blakey A. Prevalence of gastrointestinal symptoms after bacterial gastroenteritis. Study did not include a control group. BMJ. 1997;314:1903.
6. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: A six year follow up study. Gut. 2002;51:410-413.
7. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol. 2004;99:1774-1778. (Pubitemid 39237507)
8. Mearin F, Pérez-Oliveras M, Perelló A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterol. 2005;129:98-104. (Pubitemid 41002046)
9. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol. 2006;101:1894-1899.
10. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-811.
11. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci. 2008;53:982-989. (Pubitemid 351379840)
12. Cabada MM, White AC Jr. Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep. 2008;10:473-479.
13. Bercík P, Wang L, Verdú EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127:179-187. (Pubitemid 38962286)
14. Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol. 2007;102:1064-1069. (Pubitemid 46698220)
15. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5:19-30.
16. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis. 2006;42:1283-1288.